Dr. Ajaykumar Rao Provides Perspective to Healthline on New Research That Found Semaglutide May Help Lower Risk of Developing Cardiovascular Disease

Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism and Associate Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Associate Professor in the Center for Metabolic Disease Research at Temple University Hospital, provided perspective to Healthline on new research that found semaglutide (also known as Wegovy or Ozempic) may help lower the risk of developing cardiovascular disease. The research, presented at the European Congress on Obesity, found that multiple cardiovascular risk factors, including blood pressure, total cholesterol and triglycerides, decreased after a year of taking semaglutide. Dr. Rao was not involved in the study.